Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein

Croatian Medical Journal

Volumn 44, Issue 4, 2003, Pages 455-462

  Joshi, Bharat H ^a   Leland, Pamela ^a   Puri, Raj K ^a,b  

^a Center for Biologics Evaluation/Res   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bacterial toxins; Fluorescent antibody technique; Interleukin 13; Medulloblastoma; Pseudomonas aeruginosa; Receptors, interleukin; Reverse transcriptase polymerase chain reaction

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 2; INTERLEUKIN 2GAMMA C; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MEDULLOBLASTOMA; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ANALYSIS;

CEREBELLAR NEOPLASMS; CYTOTOXINS; EXOTOXINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; MALE; MEDULLOBLASTOMA; PSEUDOMONAS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0042338458     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Stevens MC, Cameron AH, Muir KR, Parkes SE, Reid H, Whitwell H. Descriptive epidemiology of primary central nervous system tumours in children: a population-based study. Clin Oncol (R Coll Radiol) 1991; 3:323-9.
2. Korshunov A, Golanov A, Ozerov S, Sycheva R. Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases. Brain Tumor Pathol 1999;16:37-44.
3. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997; 57:3272-80.
4. Jin W, Bi W, Huang ES, Cote GJ. Glioblastoma cell-specific expression of fibroblast growth factor receptor-1 beta requires an intronic repressor of RNA splicing. Cancer Res 1999;59:316-9.
5. Kim CJ, Matsuo T, Lee KH, Thiele CJ. Up-regulation of insulin-like growth factor-II expression is a feature of TrkA but not TrkB activation in SH-SY5Y neuroblastoma cells. Am J Pathol 1999;155:1661-70.
6. Liu Y, Lehar S, Corvi C, Payne G, O'Connor R. Expression of the insulin-like growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells. Cancer Res 1998;58:570-6.
7. Zumkeller W, Schwab M. Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis: potential diagnostic and therapeutic perspectives. Horm Metab Res 1999;31:138-41.
8. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, Mclendon RE, Bigner DD. Tumor-antigen in astrocytic glioma. Glia 1995;15:244-56.
9. Debiec-Rychter M, Liberski PP. Molecular changes involved in the carcinogenesis of brain tumors. Folia Neuropathol 1994;32:199-203.
10. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TFCRM107 in patients with malignant brain tumors [see comments]. Nat Med 1997;3:1362-8.
11. MacDonald TJ, DeClerck YA, Laug WE. Urokinase induces receptor mediated brain tumor cell migration and invasion. J Neurooncol 1998;40:215-26.
12. Sharif TR, Sharif M. A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells. Int J Oncol 1999,14:327-35.
13. Sharif TR, Sharif M. Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples. Int J Oncol 1999;15:237-43.
14. Omura Y, Shimotsura Y, Ooki M, Noguchi T. Estimation of the amount of telomere molecules in different human age groups and the telomere increasing effect of acupuncture and shiatsu on St.36, using synthesized basic units of the human telomere molecules as reference control substances for the bi-digital O-ring test resonance phenomenon. Acupunct Electrother Res 1998; 23:185-206.
15. Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 1994; 58:574-81.
16. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, et al. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 1996;56:5631-7.
17. Husain SR, Behari N, Kreitman RJ, Pastan I, Puri RK. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res 1998;58:3649-53.
18. Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri RK. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res 2001;61:8058-61.
19. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1995;1:1253-8.
20. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001;92:168-75.
21. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000;60:1168-72.
22. Kawakami M, Leland P, Kawakami K, Puri RK. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res 2000;12:459-67.
23. Kawakami M, Kawakami K, Puri RK. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 2002;1:999-1007.
24. Murata T, Noguchi PD, Puri RK. Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. J Biol Chem 1995;270:30829-36.
25. Murata T, Obiri NI, Puri RK. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors. Int J Mol Med 1998;1:551-7.
26. Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997;238:90-4.
27. Murata T, Obiri NI, Puri RK. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer 1997;70:230-40.
28. Murata T, Husain SR, Mohri H, Puri RK. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 1998;10:1103-10.
29. Obiri NI, Leland P, Murata T, Debinski W, Puri RK. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol 1997;158:756-64.
30. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995;270:8797-804.
31. Obiri NI, Murata T, Debinski W, Puri RK. Modulation of interleukin (IL)-13 binding and signaling by the gamma c chain of the IL-2 receptor. J Biol Chem 1997;272:20251-8.
32. Kuznetsov VA, Puri RK. Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: suppression of IL-13 binding by IL-2 receptor gamma chain. Biophys J 1999;77:154-72.
33. Keles GE, Berger MS, Srinivasan J, Kolstoe DD, Bobola MS, Silber JR. Establishment and characterization of four human medulloblastoma-derived cell lines. Oncol Res 1995;7:493-503.
34. Joshi BH, Leland P, Silber J, Kreitman RJ, Pastan I, Berger M, et al. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br J Cancer 2002;86:285-91.
35. Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 1993;91:88-93.
36. Joshi BH, Kawakami K, Leland P, Puri RK. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002;8:1948-56.
37. Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995;270:16775-80.
38. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996;87:4333-9.
39. Kreitman RJ, Puri RK, McPhie P, Pastan I. Circularly permuted interleukin 4 retains proliferative and binding activity. Cytokine 1995;7:311-8.
40. Oshima Y, Joshi BH, Puri RK. Conversion of interleukin-13 into a high affinity agonist by a single amino acid substitution. J Biol Chem 2000;275:14375-80.
41. Puri RK, Ogata M, Leland P, Feldman GM, FitzGerald D, Pastan I. Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. Cancer Res 1991;51:3011-7.
42. Puri RK, Leland P, Obiri NI, Husain SR, Mule J, Pastan I, et al. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. Cell Immunol 1996;171:80-6.
43. Leland P, Obiri N, Aggarwal BB, Puri RK. Suramin blocks binding of interleukin-4 to its receptors on human tumor cells and interleukin-4-induced mitogenic response. Oncol Res 1995;7:227-35.
44. Murata T, Puri RK. Comparison of IL-13- and IL-4-induced signaling in EBV- immortalized human B cells. Cell Immunol 1997;175:33-40.
45. Murata T, Noguchi PD, Puri RK. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol 1996;156:2972-8.
46. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 2001;194:1743-54.
47. Kawakami K, Kawakami M, Puri RK. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. J Immunol 2002;169:7119-26.
48. Zhang JG, Hilton DJ, Willson TA, McFarlane C, Roberts BA, Moritz RL, et al. Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains. J Biol Chem 1997;272:9474-80.
49. Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, et al. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res 1997;3:151-6.
50. Husain SR, Puri RK. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood 2000;95:3506-13.
51. Debinski W, Miner R, Leland P, Obiri NI, Puri RK. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem 1996;271:22428-33.
52. Di Massimo AM, Di Loreto M, Pacilli A, Raucci G, D'Alatri L, Mele A, et al. Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata. Br J Cancer 1997;75:822-8.
53. LeMaistre CF, Meneghetti C, Howes L, Osborne CK. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat 1994;32:97-103.
54. Martell LA, Agrawal A, Ross DA, Muraszko KM. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 1993;53:1348-53.
55. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6:2157-65.
56. Weber F, Asher A, Bucholtz R, Berger M, Prados M, Chang S, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas Exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol. In press 2003.
57. Weingart J, Grossman SA, Bohan E, Fisher JD, Strauss L, Puri RK. Phase I/II study of interstitial infusion of IL13-PE38QQR cytotoxin in recurrent malignant glioma [abstract]. First Quadrennial meeting - World Federation of Neuro-Oncology; 2001 Nov 15-17; Washington (DC), USA. Available from: http://www.soc-ne uro-onc.org/meetings/2001/annmeetprgsched.pdf. Accessed: July 1, 2003..
58. Weingart J, Strauss L, Grossman SA, Markert J, Tatter S, Fisher JD, et al. Intratumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma: phase I/II study. Alexandria (VA): American Society of Clinical Oncology Publications; 2002. Abstract No. 2088.
59. Prados M, Lang F, Strauss L, Fleming C, Alalpe K, Kunwar S, et al. Intratumoral and intracerebral microinfusion of IL13-PE38QQR cytotoxin: phase I/II study of pre- and post-resection infusions in recurrent resectable malignant glioma. Alexandria (VA): American Society of Clinical Oncology; 2002.
60. Lang F, Kunwar S, Strauss L, Piepmeier J, McDermott M, Fleming C, et al. A clinical study of convection-enhanced delivery of IL-13PE38QQR cytotoxin. Pre- and post-resection of recurrent GBM. Chicago (IL): American Society of Neuro-Oncologists; 2002.
61. Prados M, Lang F, Sherman J, Strauss L, Fleming C, Alalpe K, et al. Convection-enhanced delivery (CED) by positive pressure infusion for intra-tumoral and peri-tumoral administration of IL-13PE38QQR a recombinant tumor-targeted cytotoxin in recurrent malignant glioma. J Neurooncol 2002;4:S78.
62. Prados M, Lang F, Strauss L, Fleming C, Aldape K, Kunwar S, et al. Pre and post-resection interstitial infusions of IL13-PE38QQR cytotoxin: Phase I study in recurrent respectable malignant glioma. First Qudrennial meeting - World Federation of Neuro-Oncology; 2001 Nov 15-17; Washington, DC. Rockville (MD): CBER Research, Food and Drug Administration; 2001.